Developing a new mRNA vaccine adjuvant for influenza
MRNA VACCINE DEVELOPMENT
This study is testing a new way to boost the effectiveness of flu vaccines by using a special ingredient that helps your immune system respond better, so you can get better protection against the flu.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Flag Bio, INC. NIH-funded |
| Lab location | 1 site (East Aurora, United States) |
| Project ID | NIH-11203921 on NIH RePORTER |
What this research studies
This research focuses on creating mRNAFlag, a novel vaccine adjuvant designed to enhance the immune response to influenza vaccines. The approach involves using an mRNA transcript that encodes a modified TLR5 agonist, which is expected to improve the effectiveness of the influenza mRNA vaccine. The vaccine will utilize a specific hemagglutinin from the H1N1 virus and will be formulated in a lipid nanoparticle system similar to that used in successful COVID-19 vaccines. Patients may benefit from improved protection against influenza through enhanced vaccine responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at higher risk for influenza complications, such as the elderly, young children, and those with underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have contraindications to vaccination may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective influenza vaccines, providing better protection for patients during flu seasons.
How similar studies have performed: Other research has shown promise in using mRNA technology for vaccines, particularly with COVID-19, indicating a potential for success in this novel application for influenza.
Where this research is happening
East Aurora, United States
- Flag Bio, INC. — East Aurora, United States (Active)
Researchers
- Principal investigator: Andrianova, Katerina — Flag Bio, INC.
- Study coordinator: Andrianova, Katerina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.